Maintenance of therapeutic plasma aprotinin levels during prolonged cardiopulmonary bypass using a large-dose regimen

Anesthesia and Analgesia

Volumn 83, Issue 6, 1996, Pages 1189-1192

  Bennett Guerrero, Elliott ^a   Sorohan, Jonathan G ^b   Howell, Scott T ^b   Ayuso, Liza ^c   Cardigan, Rebecca A ^d   Newman, Mark F ^b   Mackie, Ian J ^d   Reves, J G ^b   Mythen, Michael G ^b  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; DRUG BLOOD LEVEL; FEMALE; HEALTH CARE COST; HUMAN; MALE; PRIORITY JOURNAL;

EID: 0029855977     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000539-199612000-00010     Document Type: Article

References (13)

1. Heart and Stroke Facts. 1995 statistical supplement. Dallas, TX: American Heart Association, 1995:1-23.
2. Taylor KM. Perioperative approaches to coagulation defects. Ann Thorac Surg 1993;56:S78-82.
3. Jobes DR, Ellison N. Hemotherapy: control of hemostasis and blood replacement. In Estafanous FG, Barash PG, Reves JG, eds. Cardiac anesthesia: principles and clinical practice. Philadelphia: JB Lippincott, 1994:597-620.
4. Royston D. High dose aprotinin therapy: a review of the first five years' experience. J Cardiothorac Vase Anesth 1992;6:76-100.
5. Dietrich W, Dilthey G, Spannagl M, et al. Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celite and kaolin activated clotting time in heparin-pretreated patients undergoing open-heart surgery. Anesthesiology 1995;83:679-689.
6. Dietrich W, Spannagl M, Jochum M, et al. Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization. Anesthesiology 1990;73:1119-26.
7. Bidstrup BP, Royston D, Sapsford RN, Taylor KM. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). J Thorac Cardiovasc Surg 1989;97:364-372.
8. van Oeveren W, Jansen NJ, Bidstrup BP, et al. Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. Ann Thorac Surg 1987;44:640-5.
9. Levy JH, Bailey JM, Salmenperä M. Pharmacokinetics of aprotinin in preoperative cardiac surgical patients. Anesthesiology 1994;80:1013-8.
10. Gallimore MJ, Fuhrer G, Heller W, Hoffmeister HE. Augmentation of kallikrein and plasmin inhibition capacity by aprotinin using a new assay to monitor therapy. Kinins V. Adv Exp Med Biol 1989;247B:55-60.
11. Holley FO, Ponganis KV, Stanski DR. Effect of cardiopulmonary bypass on the pharmacokinetics of drugs. Clin Pharmacokinet 1982;7:234-251.
12. Flezzani P, Alvis MJ, Jacobs JR, et al. Sufentanil disposition during cardiopulmonary bypass. Can J Anaesth 1987;34:566-9.
13. Jacobs JR, Croughwell ND, Goodman DK, et al. Effect of hypothermia and sampling site on blood esmolol concentrations. J Clin Pharmacol 1993;33:360-5.